Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 induces Th2 immune response against amyloid-β in wild-type mouse

Neuroscience Letters

Volumn 505, Issue 2, 2011, Pages 128-133

  Li, Yu ^a   Ma, Ying ^a   Zong, Li Xia ^a   Xing, Xiao Na ^a   Sha, Sha ^a   Cao, Yun Peng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus vaccine; Alzheimer's disease; Amyloid

Indexed keywords

ADENOVIRUS VECTOR; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[3-10]; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 10; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; INOCULATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; SPLEEN CELL; TH2 CELL; WILD TYPE;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL POLARITY; CELLS, CULTURED; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; REPETITIVE SEQUENCES, AMINO ACID; SPLEEN; TH2 CELLS; VIRAL VACCINES;

EID: 81055155808     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.10.005     Document Type: Article

References (42)

1. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
2. Acero G., Manoutcharian K., Vasilevko V., Munguia M.E., Govezensky T., Coronas G., Luz-Madrigal A., Cribbs D.H., Gevorkian G. Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits. J. Neuroimmunol. 2009, 213:39-46.
3. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2023-2028.
4. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 2001, 1:209-219.
5. Chauhan N.B., Siegel G.J. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci. Lett. 2005, 375:143-147.
6. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., Babikyan D., Kesslak P., Kieber-Emmons T., Cotman C.W., Agadjanyan M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 2003, 15:505-514.
7. D'Arrigo C., Tabaton M., Perico A. N-terminal truncated pyroglutamyl beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than the full-length Abeta1-42. Biopolymers 2009, 91:861-873.
8. Daly L.M., Johnson P.A., Donnelly G., Nicolson C., Robertson J., Mills K.H. Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. Vaccine 2005, 23:963-974.
9. Frenkel D., Kariv N., Solomon B. Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine 2001, 19:2615-2619.
10. Gevorkian G., Petrushina I., Manoutcharian K., Ghochikyan A., Acero G., Vasilevko V., Cribbs D.H., Agadjanyan M.G. Mimotopes of conformational epitopes in fibrillar beta-amyloid. J. Neuroimmunol. 2004, 156:10-20.
11. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562. AN1792(QS-21)-201 Study Team.
12. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
13. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
14. Kaufman D.R., Bivas-Benita M., Simmons N.L., Miller D., Barouch D.H. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J. Virol. 2010, 84:5986-5996.
15. Kim H.D., Cao Y., Kong F.K., Van Kampen K.R., Lewis T.L., Ma Z., Tang D.C., Fukuchi K. Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine 2005, 23:2977-2986.
16. Kim H.D., Maxwell J.A., Kong F.K., Tang D.C., Fukuchi K. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem. Biophys. Res. Commun. 2005, 336:84-92.
17. Kim H.D., Tahara K., Maxwell J.A., Lalonde R., Fukuiwa T., Fujihashi K., Van Kampen K.R., Kong F.K., Tang D.C., Fukuchi K. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J. Gene Med. 2007, 9:88-98.
18. Klinman D.M., Klaschik S., Tomaru K., Shirota H., Tross D., Ikeuchi H. Immunostimulatory CpG oligonucleotides: effect on gene expression and utility as vaccine adjuvants. Vaccine 2010, 28:1919-1923.
19. Lambracht-Washington D., Qu B.X., Fu M., Eagar T.N., Stüve O., Rosenberg R.N. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 2009, 302:1796-1802.
20. Lemiale F., Kong W.P., Akyürek L.M., Ling X., Huang Y., Chakrabarti B.K., Eckhaus M., Nabel G.J. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 2003, 77:10078-10087.
21. Ma Y., Li Y., Zong L.X., Xing X.N., Zhang W.G., Cao Y.P. Improving memory and decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with Aβ3-10 repeat fragment plasmid by reducing Aβ deposition and inflammatory response. Brain Res. 2011, 1400:112-124.
22. Matsumo Y., Sakuma H., Miyakoshi A., Tsukada Y., Kohyama K., Park I.K., Tanuma N. Characterization of relapsing autoimmune encephalomyelitis and its treatment with decoy chemokine receptor genes. J. Neuroimmunol. 2005, 170:49-61.
23. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M., St. George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
24. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
25. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J. 2007, 21:2135-2148.
26. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P.B., Head E., Biragyn A., Cribbs D.H., Agadjanyan M.G. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One 2008, 3:e2124.
27. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer's disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
28. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
29. Petrushina I., Ghochikyan A., Mktrichyan M., Mamikonyan G., Movsesyan N., Davtyan H., Patel A., Head E., Cribbs D.H., Agadjanyan M.G. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J. Neurosci. 2007, 27:12721-12731.
30. Quintana F.J., Rotem A., Carmi P., Cohen I.R. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J. Immunol. 2000, 165:6148-6155.
31. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
32. Schlenzig D., Manhart S., Cinar Y., Kleinschmidt M., Hause G., Willbold D., Funke S.A., Schilling S., Demuth H.U. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 2009, 48:7072-7078.
33. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G., Lemere C.A. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging 2007, 28:813-823.
34. Segal B.M., Klinman D.M., Shevach D.M. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J. Immunol. 1997, 158:5087.
35. Smolianov V., Dehmel T., Vollmar P., Mausberg A.K., Kieseier B.C., Hemmer B., Hartung H.P., Hofstetter H.H. Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG Oligonucleotide. J. Neuroinflammation 2011, 8:59.
36. Subramanian S., Divya Shree A.N. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats. Neurosci. Lett. 2008, 436:219-222.
37. Torres K.C., Dutra W.O., Gollob K.J., Endogenous IL-4 IFN-gamma are essential for expression of Th2, but not Th1 cytokine message during the early differentiation of human CD4+ T helper cells. Human Immunol. 2004, 65:1328-1335.
38. Vellas B., Black R., Thal L.J., Fox N.C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M., Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alz. Res. 2009, 6:144-151. AN1792 (QS-21)-251 Study Team.
39. Wang C.Y., Finstad C.L., Walfield A.M., Sia C., Sokoll K.K., Chang T.Y., Fang X.D., Hung C.H., Hutter-Paier B., Windisch M., Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine 2007, 25:3041-3052.
40. Wirths O., Bethge T., Marcello A., Harmeier A., Jawhar S., Lucassen P.J., Multhaup G., Brody D.L., Esparza T., Ingelsson M., Kalimo H., Lannfelt L., Bayer T.A. Pyroglutamate Abeta pathology in APP/PS1KI mice. sporadic and familial Alzheimer's disease cases. J. Neural Transm. 2010, 117:85-96.
41. Wolfe M.S. Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug Discov. 2002, 1:859-866.
42. Zou J., Yao Z., Zhang G., Wang H., Xu J., Yew D.T., Forster E.L. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. J. Neurol. Sci. 2008, 272:87-98.